Skip to content

Prevalence of Spontaneous Pneumothorax in BHD

Prevalence of Birt-Hogg-Dubé Syndrome Among Patients With (Hereditary) Spontaneous Pneumothorax

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02916992
Enrollment
200
Registered
2016-09-28
Start date
2016-09-30
Completion date
2017-07-31
Last updated
2016-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous Pneumothorax

Keywords

spontaneous pneumothorax, familial pneumothorax, Birt-Hogg-Dube syndrome, prevalence, FLCN mutation, Lung cysts, BHD, inherited disease, genetic disease, primary pneumothorax, CAT scan, CT scan

Brief summary

To assess the prevalence of BHD (Birt-Hogg-Dubé syndrome) among patients with spontaneous pneumothorax. Patients who were treated for primary spontaneous pneumothorax in Rijnstate hospital are to be included. Patients will receive a questionnaire. When given consent, the investigators will invite them for a one-time visit to the out-patient clinic. Patients will be asked for a blood sample to determine pathogenic FLCN (folliculin) mutations and a pulmonary CT scan for evaluation of presence of lung cysts.

Detailed description

Based on the results of the pilot study in VUmc \*Free University Medical Center), in which 3 out of 40 tested patients had a pathological FLCN mutation, the investigators decided to extend the study to a second center; Rijnstate Hospital Arnhem. In this hospital a retrospective search was performed; patients who were treated for primary spontaneous pneumothorax were included. In the dossiers the investigators searched for medical history, pneumothorax side and recurrence, diagnostic imaging, treatment, co-morbidity, complications of treatment, skin abnormalities, kidney disease, smoking behavior, medication, and familial incidence of pneumothorax and other diseases. Patients will receive a letter with explanation of the research and a questionnaire in which the investigators ask them their about the medical status, co-morbidity, pneumothorax (number and side), smoking behavior, use of drugs, familial incidence of pneumothorax and other diseases. The population will be formed out of patients who have returned the fully filled in questionnaire and who have given permission to receive information for further research. This further information will consist of an information letter on BHD syndrome and a consent form for a one-time visit to the out-patient clinic of Rijnstate hospital. Investigators expect that about 200 patients will return the fully filled in questionnaire and give their consent for further research. In a one-time visit in out-patient clinic, there will be given personal information on BHD syndrome and there will be performed physical examination for finding fibrofolliculomas. A pulmonary CT scan for evaluation of presence of lung cysts will be performed. Two samples of venous blood will be collected to access information on DNA diagnostics for pathogenic FLCN mutations. These are associated with the BHD syndrome. This last diagnostic testing will be performed in VUmc (Vrije Universiteit medisch centrum or Free University Medical Centre).

Interventions

RADIATIONCT scan of the thorax

A low dose CT scan of the thorax (2mSv) wil be performed once.

GENETICblood sample for FLCN mutation analyses

A venous punction in order to withdraw 16ml blood is undertaken once.

Sponsors

Prof. Dr. Jaap Swieringa stichting
CollaboratorUNKNOWN
Mr. Willem Bakhuys Roozeboomstichting
CollaboratorUNKNOWN
Rijnstate Hospital
CollaboratorOTHER
Hans Smit
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* treated in Rijnstate hospital for primary spontaneous pneumothorax * informed consent

Exclusion criteria

* secondary or iatrogenic pneumothorax

Design outcomes

Primary

MeasureTime frameDescription
presence of pathogenic FLCN mutations6 monthsby assessing blood samples

Secondary

MeasureTime frameDescription
presence of lung cysts6 monthsvisible on pulmonary low dose CT

Countries

Netherlands

Contacts

Primary ContactJincey D. Sriram, MD, MSc
JSriram@Rijnstate.nl0880058888
Backup ContactHans JM Smit, MD,PhD
HSmit@Rijnstate.nl0880058888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026